Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells 7,394 Shares of Company Stock

Key Points

• Insider sale: Philippe Menu sold 7,394 SOPHiA GENETICS shares at an average price of $8.13, for proceeds of approximately $60,113. The Rule 10b5-1 transaction covered tax withholding on vested equity awards and reduced his ownership by 3.55%.
• Stock performance and fundamentals: SOPH shares fell 3.1% to $7.15, while the company reported a quarterly EPS loss of $0.26, below expectations, despite revenue of $23.31 million exceeding estimates.
• Analyst outlook: Ratings remain mixed, resulting in a consensus “Hold” recommendation and an average price target of $10.00; three analysts rate the stock Buy, one Hold and one Sell.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Philippe Menu sold 7,394 shares of the firm's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $8.13, for a total value of $60,113.22. Following the transaction, the insider directly owned 200,993 shares in the company, valued at $1,634,073.09. This trade represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Tuesday, August 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.68, for a total value of $43,400.00.
• On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total transaction of $37,600.00.
• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total transaction of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $28,500.00.

SOPHiA GENETICS Trading Down 3.1%

NASDAQ:SOPH traded down $0.23 during trading hours on Wednesday, hitting $7.15. The company had a trading volume of 432,750 shares, compared to its average volume of 308,157. SOPHiA GENETICS SA has a 52 week low of $3.75 and a 52 week high of $8.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The stock has a 50-day moving average price of $7.82 and a 200 day moving average price of $6.12. The company has a market capitalization of $599.81 million, a PE ratio of -6.22 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. On average, equities research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SOPH has been the topic of a number of recent research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. BTIG Research upped their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Finally, HC Wainwright lifted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of "Hold" and a consensus price target of $10.00.

Institutional Trading of SOPHiA GENETICS

A number of large investors have recently made changes to their positions in the business. AWM Investment Company Inc. purchased a new position in shares of SOPHiA GENETICS in the 2nd quarter worth approximately $9,809,000. Principal Financial Group Inc. grew its stake in SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock worth $6,976,000 after acquiring an additional 9,800 shares in the last quarter. Hodges Capital Management Inc. purchased a new position in SOPHiA GENETICS during the 1st quarter worth $2,157,000. Sei Investments Co. bought a new stake in shares of SOPHiA GENETICS in the first quarter valued at about $1,772,000. Finally, 1492 Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 8.4% in the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company's stock worth $1,117,000 after purchasing an additional 17,406 shares during the period. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.